Tumbling revenue was overshadowed by a vast improvement in the bottom line.
This could be a buying opportunity.
The footwear specialist got tripped up by dismal forward guidance. But its weakness might be temporary.
Investors are happy the biotech ended a lawsuit hanging over its head.
The natural gas driller’s production update didn’t have the desired effect.
The content delivery expert crushed Wall Street's Q1 estimates and should do far better in the near future.
The Eagle Ford Shale driller’s output came up short.
Weak revenue growth from Philip Morris and concerns about its vape product sent both tobacco stocks lower.
Talks of a waiver on debt covenants is never a good sign for a company.
The specialty retailer is implementing a new three-year plan to turn its business around. Here's what investors need to know.
Weak sales and some trouble with the bottom line have investors worried.
A solid first-quarter earnings report and upbeat outlook are making the credit card giant's investors smile
The pharma company announced a debt offering that has Wall Street scrambling.
Shares of the meal-kit provider seemed to bounce on a Twitter rumor about an acquisition.
A strong report from a competitor was enough to send the stock higher.
One day after ESPN helped Roku score a touchdown, Best Buy and Amazon are forcing a fumble.
For the time being at least, BRF is cleared of "food safety concerns" and able to produce more chicken.
The tobacco products leader suffered multiple analyst downgrades today.
Big Blue left investors feeling, well, blue following an unconvincing earnings report.
A U.S. acquisition could change SunPower's domestic fortunes as early as this summer.
This analyst expects double-digit revenue growth from Twitter in 2018.
The company's lead drug candidate was approved by regulators -- for real this time.
The biopharma announced a public offering of common stock.
The streaming video veteran added more new subscribers than expected, mostly overseas. That's exactly what investors wanted to see.
New data suggesting the FDA's OK with its marijuana drug has investors cheering.
Geron's experimental blood cancer drug remains a top priority for the pharma behemoth Johnson & Johnson.
J.Jill investors are more optimistic after insider buying, but challenges remain.
The company got a new live sports offering and an institutional investor.
Stock in the advertising dynamo retrenches after a strong performance in February.
One report says Volkswagen may be contemplating a complete buyout.
An FAA contract win is revealed, but are investors overreacting?
30% of the company's sales just vanished.
Eldorado Resorts Inc is making bold moves by acquiring new resorts today.
Shares of the meal-kit provider gained today as short sellers seem to close out their bets.
The biopharma reported encouraging data from a phase 1 trial. Er, wait, what?
Celldex's highly anticipated breast cancer drug fails to hit the mark in a midstage trial.
Soft retail-store traffic trends stymied the Victoria's Secret parent last month.
Another solid earnings report, as well as news on the acquisitions front, boosted Momo stock last month.
The real-estate services veteran expanded a quick-turn service for home flippers to a third market, and neither analysts nor investors liked the idea.
It's down nearly 9% on a negative analyst note from Nomura.
The catalysts for Baidu's sell-offs last month might not be the biggest concerns for long-term investors.
President Donald Trump strikes again.
Shares tumble after a Wall Street analyst cuts his rating. Here's what investors need to know.
Beating analysts' estimates by $0.02, Kratos reported fourth-quarter earnings per share of $0.09, but it wasn't enough to lift investors' spirits.
Is Bitauto stock in value-play territory after recent sell-offs?
Himax stock has bounced back from selloffs last month, but it looks like the company's share price will continue to be highly volatile.
The Chinese e-commerce platform is serving up impressive growth and still has room to run.
Control4's stock has struggled in 2018, but it's still up roughly 40% over the last year.
Failing to report a profit for the fifth consecutive year wasn't enough to dampen shareholders' spirits last month.
The company lost a major distribution partner.